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ABSTRACT
The Immuno Polymorphism Database (IPD)
(http://www.ebi.ac.uk/ipd/) is a set of specialist
databases related to the study of polymorphic
genes in the immune system. The IPD project
works with specialist groups or nomenclature
committees who provide and curate individual
sections before they are submitted to IPD for
online publication. The IPD project stores all the
data in a set of related databases. IPD currently
consists of four databases: IPD-KIR, contains the
allelic sequences of Killer-cell Immunoglobulin-like
Receptors, IPD-MHC, is a database of sequences of
the Major Histocompatibility Complex of different
species; IPD-human platelet antigens, alloantigens
expressed only on platelets and IPD-ESTDAB,
which provides access to the European Searchable
Tumour cell-line database, a cell bank of immuno-
logically characterised melanoma cell lines. The
data is currently available online from the website
and ftp directory.
INTRODUCTION
The study of the immune system constitutes many dif-
ferent complex areas of research. The Immuno
Polymorphism Database (IPD) is a set of specialist
databases related to the study of polymorphic genes of
the immune system. The IPD project works with specialist
groups or nomenclature committees, which each curate a
diﬀerent section of the project. IPD currently consists of
four databases: IPD-KIR, contains the allelic sequences
of Killer-cell Immunoglobulin-like Receptors (KIR);
IPD-MHC, is a database of sequences of the Major
Histocompatibility Complex (MHC) of diﬀerent species;
IPD-human platelet antigens (IPD-HPA), alloantigens
expressed only on platelets and IPD-ESTDAB, which
provides access to the European Searchable Tumour
cell-line database (ESTDAB), a cell bank of immuno-
logically characterised melanoma cell lines. By providing
a centralised resource for the work of diﬀerent groups it is
hoped we can bring together similar data to aid in the
study and analysis of this area.
This is done by contacting various expert groups, such
as the nomenclature committees for certain genes, and
inviting them to contribute their data to a central
resource. The individual nomenclature committees are
all established within their own ﬁeld, their continuing
role being the identiﬁcation and naming of new alleles
based on the submission of new sequences to generalist
databases like the European Molecular Biology
Laboratory’s nucleotide sequence database (also known
as EMBL-Bank) (1), the National Center for
Biotechnology Information’s GenBank (2) and the DNA
DataBank of Japan (DDBJ) (3). The main diﬀerence
between the data held within a specialist system like IPD
and the generalist databases is the further curation of
the ﬁles by experts in the relevant ﬁeld. This additional
step allows for improvements in data quality and the
addition of more specialised information. This may
result in there being diﬀerences in the entries kept in the
diﬀerent databases; in this case the entry in IPD should be
considered the most accurate. The inclusion of some
nomenclature committees has meant the online publica-
tion of sequence alignments for the ﬁrst time. This is par-
ticularly important when it comes to the sequences of
polymorphic genes. Also because the IPD project is able
to provide the work of diﬀerent committees in a common
format, it is easier to compare the sequences of diﬀerent
species.
The IPD project stores all the data in a set of related
databases. Those sections with similar data, IPD-KIR and
IPD-MHC share the same database structure. The sharing
of a common database structure makes it easier to imple-
ment common tools for data submission and retrieval.
Other unrelated sections like IPD-ESTDAB currently
have their own unique structure.
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The KIR are members of the immunoglobulin super
family (IgSF) formerly called Killer-cell Inhibitory
Receptors. KIRs have been shown to be highly
polymorphic both at the allelic and haplotypic levels (4).
They are composed of two or three Ig-domains, a
transmembrane region and cytoplasmic tail, which can
in turn be short (activatory) or long (inhibitory). The
Leukocyte Receptor Complex (LRC), which encodes
KIR genes, has been shown to be polymorphic, polygenic
and complex in a manner similar to the MHC. Because of
the complexity in the KIR region and KIR sequences a
KIR Nomenclature Committee was established in 2002, to
undertake the naming of KIR allele sequences. The ﬁrst
KIR Nomenclature report was published in 2003 (5),
which coincided with the ﬁrst release of the IPD-KIR
database. The number of oﬃcially named KIR alleles
has increased since the initial release which contained 89
alleles. As of September 2009, there are over 450 alleles,
which code for over 230 unique protein sequences. This
has meant that since its initial release there have been nine
further releases of the IPD-KIR database, the latest being
in February 2009.
The online tools available for IPD-KIR include those
for performing allele queries, sequence alignments and cell
queries. As the database is based on the work of a nomen-
clature committee, the website includes links to a portable
document format (PDF) ﬁle of recent nomenclature
reports. From the data contained within these reports
the database is also able to provide individual allele
reports (Figure 1). These pages contain the oﬃcial allele
name, any previous designations, the EMBL, GenBank,
or DDBJ accession number(s) and a reference linked
wherever possible to the PubMed abstract. Where
possible additional details on the source of sequence are
also provided. This source material is normally in the form
of a cell-line or DNA from which each allele in the
database was isolated and characterised and it’s availabil-
ity. The information contained within this dataset can be
searched independently from the allele data.
Within each IPD section alleles of a particular gene
may diﬀer from each other by as little a single nucleotide.
With sometimes hundreds of alleles for a particular gene
we need to be able to graphically represent where these
diﬀerences lie. These polymorphic positions are also
often conserved within certain groups of alleles. For this
reason the sequences are displayed as multiple sequence
alignments which highlight the polymorphic positions.
These alignments allow a visual interpretation of
sequence similarity, so that polymorphic positions can
easily be identiﬁed and motifs found in multiple alleles
are easily identiﬁed. The sequence alignments are available
via a link from the section homepage. The sequence align-
ment tool uses the same basic interface for both IPD-KIR
database and IPD-MHC. The interface provided
(Figure 2) lets the user deﬁne a number of key variables
for the alignments, before producing an online output,
which can be printed or downloaded. The ﬁrst step in
any alignment is to select the locus of interest. The tool
provides a drop-down list of all loci. The selection of a
locus automatically updates the list of features, which can
be aligned, as well as the default reference sequence used
for the alignment. The types of feature available for align-
ment are the nucleotide coding sequence and individual
exons, the signal peptide, mature protein and full-length
protein sequence. We also include the genomic sequence,
which covers some of the 50 and 30 untranslated regions,
exons and introns into the database for over half of the
alleles in the KIR system. The alignment tool options also
allow the user to display a subset of alleles of a particular
locus, omit alleles unsequenced for a particular region and
also to align against a particular reference or consensus
sequence. The alignment tool uses standard formatting for
the display of sequence alignments. The alignment tool
does not perform a sequence alignment each time it is
used, but it extracts pre-aligned sequences, allowing for
faster access. The alignments adhere to a number of
conventions for displaying evolutionary events and num-
bering. The numbering of the alignments is based upon the
sequence of the reference allele. For a nucleotide sequence,
the A of the initiation Methionine codon is denoted
nucleotide +1 and the nucleotide 50 to +1 is numbered
 1. There is no nucleotide zero (0). All numbering is based
on the ATG of the reference sequence. If a nucleotide
sequences is displayed in codons, then the protein num-
bering is applied. For amino acid-based alignments, the
ﬁrst codon of the mature protein, after cleavage of the
signal sequence is labelled codon 1 and the codon 50 to
this is numbered  1. In all sequences the following
conventions are used. Where identity to the reference
sequence is present the base will be displayed as a
hyphen (-). Non-identity to the reference sequence is
shown by displaying the appropriate base at that
position. Where an insertion or deletion has occurred,
this is be represented by a period (.). If the sequence is
unknown at any point in the alignment, this is be repre-
sented by an asterisk (*). In protein alignments for null
alleles, the ’Stop’ codons are represented by an X and the
sequence following the termination codon, is not marked
up and appears blank. The ﬂexibility of the new alignment
tool means that unlike in previous alignments you can
now display a small subset of sequences against an
allele of your choice, using a number of display options
(Figure 3).
Further recent additions to the tools available from
the IPD-KIR site include a KIR ligand calculator (6).
The ligand calculator allows the user to deﬁne which
KIR ligands are present in a transplant setting based on
the HLA typing of a patient and prospective donor. This
is because recent transplant strategies based on KIR-
ligand mismatch to predict NK cell alloreactivity have
resulted in less relapse, less GvHD and better overall
survival in patients with acute myeloid leukaemia
(AML) (7). The KIR-ligands are HLA molecules that
can be grouped into three major categories based on the
amino acid sequence determining the KIR-binding
epitopes in HLA-C and HLA-B molecules. All expressed
HLA-C alleles are of the C1 or C2 group (8) and most
HLA-B alleles can be classiﬁed as either Bw4 or Bw6 (9).
The receptors KIR2DL1, KIR2DL2 and KIR3DL1 bind
KIR-ligand C2, C1 and Bw4, respectively, resulting in
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ligands associated with the HLA typing entered. In the
case of two digit typings the most common ligand for
the allele type is displayed. A link to the full list of
alleles matching the type given and their associated
ligands is also provided. For two digit typings any
exceptions to the list are also listed along with their
motif. For example B*15 alleles are predominately Bw6
however there are a number of alleles, B*1513 for
example, which contain the Bw4 motif. The output
classiﬁes alleles in the exceptions list as ‘Rare’ if they
have a gene frequency of <0.001 and have been seen in
less than three unrelated individuals (10). This classiﬁca-
tion allows users to make a judgement call over whether
the exceptions are likely to be seen in their samples.
The typing of KIRs is dependant on up to date lists of
alleles and primers, and many typing laboratories have
spreadsheets detailing probe hit patterns for diﬀerent
Figure 1. Allele report. The ﬁgure shows part of the report provided for each KIR allele. The report provides cross-references to an SRS entry
(KIR00002), the source entries in EMBL-BANK (AY789055-U24076) and to the seminal citations in PubMed. Other information provided includes
links to the source material, known ethnic origins and genomic DNA, cDNA and translated protein sequence.
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to update these ever-expanding lists. The new Probe and
Primer Search Tool allows uses to enter a list of primer
sequences and the tool will search the know coding
sequences for these and report any matches in ﬁle
format suitable for cutting and pasting into existing
spreadsheets. The tool is currently limited to coding
sequence but as the number of genomic sequences in the
database expands then the tool will be modiﬁed to search
these regions as well. A number of groups involved in
developing KIR typing have proposed A Community
Standard Reporting Format for KIR Genotyping Data,
these guidelines are available from the IPD-KIR website.
The IPD-KIR database is also been expanded to include
the KIR sequences from other species, most recently work
has begun on including the sequences of KIR alleles found
in Rhesus Macaques (Macaca mulatta) (11–13). These
sequences have been compiled through direct submission
and through data-mining existing sequences from the
generalist sequence databanks. The ﬁrst release of the
oﬃcial Mamu-KIR nomenclature will include 107 alleles
covering 13 loci. Further loci will be added once haplotype
studies have allowed the identiﬁcation of the genes
present. Sequences from other primate species like
Crab eating Macaque (Macaca fascicularis) have also
been submitted to the database, and these sequences
will be included at a later date. The non-human KIR
sequences will be included into the IPD-KIR section and
be accessible using the same tools as the human KIR
sequences.
Figure 3. Alignment formats available from IPD. In these alignments a dash ( ) indicates identity to the reference sequence and an asterisk (*)
denotes an unsequenced base. The ﬁrst alignment shows the default output for the nucleotide sequence of KIR3DL2. The second alignment shows
alleles from six diﬀerent genes. The pipes indicate exon boundaries and the periods represent the non-expressed pseudoexon 3 in the 2DL genes. The
ﬁnal alignment shows the translated protein sequences of the Rhesus Macaque (Macaca mulatta) 3DL1 gene.
Figure 2. Alignment interface. The alignment interface provides a user-friendly method of viewing sequence alignments with output options easily
selected.
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The MHC sequences of many diﬀerent species have been
reported (14–17), along with diﬀerent nomenclature
systems used in the naming and identiﬁcation of new
genes and alleles in each species. The sequences of the
MHC from a number of diﬀerent species are highly
conserved between species (18). The nomenclature for
MHC genes and alleles in species other than humans and
mice has historically been overseen either informally by
groups generating sequences, or by formal nomenclature
committees set up by the International Society for Animal
Genetics (ISAG). This work is now overseen by the
Comparative MHC Nomenclature Committee (19) and is
supported by ISAG and the Veterinary Immunology
Committee (VIC) of the International Union of
Immunological Societies (IUIS). By bringing the work
of diﬀerent nomenclature committees and the sequences
of diﬀerent species together it is hoped to provide a
central resource that will facilitate further research on the
MHC of each species and on their comparison.
The ﬁrst version of the IPD-MHC database involved
the work of groups specialising in non-human primates
(NHP), canines (DLA) (15,20) and felines (FLA) and
incorporated all data previously available in the IMGT/
MHC database (21). This version included data from ﬁve
species of ape, 16 species of new world monkey and 17
species of old world monkey. Since the ﬁrst version we
have been able to add sequences from cattle (BoLA),
teleost ﬁsh, rats (RT1), sheep (OLA) and swine (SLA)
(22–24). Future versions are planned to include chicken,
horse, prosimians and pinipeds (seal and sea lion)
sequences. As well as adding new species to the
database, the individual sections are also updated to
include new sequences, depending on the number of
sequences to be added updates are performed approxi-
mately twice a year.
For each species, there are some diﬀerences in the
spectrum of data covered but all sections provide
the core nomenclature pages and sequence alignments.
The nomenclature and alignments follow a similar struc-
ture to that of the IPD-KIR section, and the same basic
tools are used in both sections. Currently the IPD-MHC
sequence alignments are limited to species-speciﬁc align-
ments; however, we are working to allow cross species
alignments and the inclusion of human sequences from
the IMGT/HLA database (25) for comparative purposes.
The initial release of the database was limited to access
plain text alignments and simple HTML tables detailing
the nomenclature. We are in the process of migrating each
section to use tools similar to IPD-KIR, this means user-
deﬁned alignments, online search tools and more detailed
allele reports. Currently only the NHP section has been
moved to this new version, this was undertaken when the
nomenclature used for some species was updated. The
NHP section now contains information for over 40
species of primate, with nearly 3000 alleles.
IPD-HPA
Human platelet antigens (HPA) are alloantigens expressed
only on platelets, speciﬁcally on platelet membrane
glycoproteins. These platelet-speciﬁc antigens are immu-
nogenic and can result in pathological reactions to trans-
fusion therapy. The HPA nomenclature system was
adopted in 1990 (26,27) to overcome problems with the
previous nomenclature. Since then more antigens have
been described and the molecular basis of many has
been resolved. As a result the nomenclature was revised
in 2003 (28) and included in the IPD project. The IPD-
HPA section contains nomenclature information and
additional background material. The diﬀerent genes in
the HPA system have not been sequenced to the same
level as some of the other projects and so currently only
single nucleotide polymorphisms (SNP) are used to deter-
mine alleles. This information is presented in a grid
of SNP for each gene The IPD and HPA nomenclature
committee hope to expand this to provide full sequence
alignments when possible.
IPD-ESTDAB
IPD-ESTDAB is a database of immunologically
characterised melanoma cell lines. The database works
in conjunction with ESTDAB cell bank (29,30), which is
housed in Tu ¨ bingen, Germany and provides immuno-
logically characterised tumour cells. The IPD-ESTDAB
section of the website provides an online search facility
for cells stored in this cell bank. This enables investigators
to identify cells possessing speciﬁc parameters important
for studies of immunity, immunogenetics, gene expression,
metastasis, response to chemotherapy, and other tumour
biological experimentation. The search tool allows for
searches based on a single parameter, or clusters of
parameters on over 250 diﬀerent markers for each cell.
The detailed reports produced can be then be used to
identify cells of interest, which can then be obtained
from the cell bank.
DISCUSSION
The IPD project provides a resource for those interested in
the study of polymorphic sequences in the immune system.
By accommodating related systems in a single database,
data can be made available in common formats aiding use
and interpretation. As the projects grow and more sections
are added, the beneﬁt of having expertly curated sequences
from related areas stored in a single location is becoming
more apparent. This is particularly true of the IPD-MHC
project, where cross-species studies are able to utilise the
high quality sequences provided by the diﬀerent nomen-
clature committees in a common standardised format,
ready for use. The initial release of the IPD Database
contained only four sections and a small number of
tools; however, as the database has grown and more
sections and species have been added, more tools have
been added to the website. We plan to use the existing
database structures to house data for new sections of the
IPD project as they become available. The ﬁles will also be
made available in diﬀerent formats to download from the
website, ftp server and included into SRS, BLAST and
FASTA search engines at the European Bioinformatics
Institute (31).
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Appendix 1:
Access and contact
IPD homepage: http://www.ebi.ac.uk/ipd/
IPD-KIR homepage: http://www.ebi.ac.uk/ipd/kir/
IPD-MHC homepage: http://www.ebi.ac.uk/ipd/mhc/
IPD-HPA homepage: http://www.ebi.ac.uk/ipd/hpa/
IPD-ESTDAB homepage: http://www.ebi.ac.uk/ipd/estdab/
Contact: ipd@ebi.ac.uk
If you are interested in contributing to the project, there
are speciﬁc guidelines for the inclusion of new sections,
and interested parties should contact Prof. SGE Marsh,
steven.marsh@ucl.ac.uk for further information.
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